Statins to Prevent Immune Checkpoint Inhibitor-induced PRogression of AtherosLerosis
A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 140 participants.
Also called NCT06785974
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase
- Phase 4
- Enrolled
- 140 participants
- Registry
-
NCT06785974
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Netherlands
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT06785974. Randomized; quadruple masking; primary purpose prevention. Start 2025-02 (anticipated); primary completion 2027-02 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Statins to Prevent Immune Checkpoint Inhibitor-induced PRogression of AtherosLerosis
- Acronym
- SPIRAL
- Condition
- Atherosclerosis
- Condition
- Melanoma
- Condition
- Immune-related Adverse Event
- Intervention (Drug)
- Atorvastatin
- Intervention (Drug)
- Placebo
- Lead sponsor
- Erasmus Medical Center
- Collaborator
- Amphia Hospital
Record details
- Record id
cardio:ct-nct06785974- Content hash
3e22759d1155dfa31c8690049526ea9dd9ed16cca27225eeb35411c29ea7cc8e